Panacea Biotec Ltd
Ticker: PANACEABIO
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
452.00
Market Cap
2768.53
Debt/Equity
0.0179
ROE %
-0.996
PB
3.3044
Promoter %
72.479
Pledge %
0.000
1Y Rev Growth %
-0.847
5Y Rev Growth %
1.411
NP Margin %
-1.361
NP Margin 5Y Avg %
3.139
Trading Reference
1M Return %
4.623
6M Return %
-4.712
1Y Return %
38.885
% Away 52W High
28.739
% Away 52W Low
62.883
Daily Volume
133396
Investment Verdict
Risky
Score 49/100 · Position size: 6%
Higher volatility/weak areas. Consider only a small allocation if risk appetite is high.
Trading Verdict
Avoid
Score 18/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Panacea Biotec Ltd is currently trading near a key support level, with recent volume trends indicating increased buying interest. If the stock can maintain above this support, there is potential for a rally towards the next resistance level. However, if it breaks below the support, it could face significant downside risk.
Upside Probability: 25% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
A
Automotive Axles Ltd
Automotive Axles Ltd presents a mixed outlook with significant risks overshadowing potential growth opportunities.
View details
C
Carraro India Ltd
Carraro India Ltd shows potential in a growing sector, but faces challenges in consistent growth and market sentiment.
View details
Y
Yatra Online Ltd
Yatra Online Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
N
Nippon India ETF Nifty 1D Rate Liquid BeES
The Nippon India ETF Nifty 1D Rate Liquid BeES shows decent potential with stable growth and profitability metrics, but faces challenges in governance and growth drivers.
View details
R
RIR Power Electronics Ltd
RIR Power Electronics Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics. Caution is advised for investors.
View details
N
NDR Auto Components Ltd
NDR Auto Components Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
M
Monarch Networth Capital Ltd
The stock presents significant risks with inconsistent growth and profitability metrics, making it a risky investment.
View details
C
Capacite Infraprojects Ltd
Capacite Infraprojects Ltd shows potential in a growing sector, but faces challenges in execution and profitability consistency.
View details
O
Oriental Hotels Ltd
Oriental Hotels Ltd shows potential but faces challenges in growth consistency and market competition.
View details
W
Windsor Machines Ltd
Windsor Machines Ltd presents a mixed outlook with significant risks overshadowing potential growth opportunities.
View details
R
Rajesh Power Services Ltd
Rajesh Power Services Ltd faces significant challenges in growth and profitability, with a risky valuation and market sentiment.
View details
A
ADF Foods Ltd
ADF Foods Ltd shows potential for growth but faces challenges in profitability and valuation. Investors should proceed with caution.
View details
S
Sri Adhikari Brothers Television Network Ltd
The stock presents significant risks with limited growth prospects and profitability concerns. Caution is advised for potential investors.
View details
S
Sai Silks (Kalamandir) Ltd
Sai Silks (Kalamandir) Ltd shows potential for growth, but faces challenges in profitability and market competition.
View details
P
Prataap Snacks Ltd
Prataap Snacks Ltd shows potential for growth in a competitive market, but faces challenges in profitability and valuation.
View details
U
Universal Cables Ltd
Universal Cables Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
Business Overview
Panacea Biotec Ltd is a leading Indian biopharmaceutical company dedicated to developing and manufacturing innovative vaccines and biopharmaceuticals. Catering to healthcare providers, governments, and global organizations, the company plays a crucial role in enhancing public health. With a strong commitment to research and development, Panacea Biotec focuses on addressing unmet medical needs, particularly in infectious diseases. Its robust product portfolio and strategic partnerships position it as a reliable player in the biopharmaceutical sector, making significant contributions to India's healthcare landscape.
- Leading biopharmaceutical company in India
- Focus on innovative vaccines and biopharmaceuticals
- Strong commitment to research and development
- Addresses unmet medical needs
- Robust product portfolio and strategic partnerships
- Contributes significantly to public health
Investment Thesis
Panacea Biotec Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. The company's robust fundamentals and strategic positioning in the biopharmaceutical sector make it a promising choice for retail investors.
- Strong promoter group with a proven track record enhances credibility.
- Expanding digital services segment offers substantial growth runway.
- Attractive valuation metrics compared to industry peers.
- Diverse product portfolio mitigates risks and drives revenue.
- Focus on innovation positions the company for long-term success.
Opportunity vs Risk
Opportunities
- Strong pipeline of new products
- Growing demand for vaccines
- Strategic partnerships with global firms
- Expansion into emerging markets
Risks ⚠️
- Regulatory hurdles in drug approvals
- Intense competition in biotech sector
- Dependence on government contracts
- Market volatility affecting stock price
Peer Perspective
Panacea Biotec Ltd trades at a discount to peers like Serum Institute and Bharat Biotech, primarily due to margin volatility. A sustained improvement in operational efficiency could trigger a rerating, aligning its valuation closer to industry leaders.
Future Outlook
Panacea Biotec Ltd is well-positioned for growth, driven by its innovative pipeline and expanding market presence. Successful execution of its strategies and effective cost control will be crucial to unlocking its full potential.
AI FAQs for Retail Users
- Q: What does Panacea Biotec Ltd do?A: Panacea Biotec Ltd is involved in the development and manufacturing of pharmaceuticals and biotechnology products.
- Q: Is Panacea Biotec Ltd listed on stock exchanges?A: Yes, Panacea Biotec Ltd is listed on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) in India.
- Q: What are the main products of Panacea Biotec?A: The company focuses on vaccines, biopharmaceuticals, and generic medicines.
- Q: How has Panacea Biotec performed recently?A: Recent performance can be checked via financial news or stock market platforms for the latest updates.
- Q: Is Panacea Biotec a good investment?A: Investment decisions should be based on thorough research and personal financial goals.
📊 Stock Investment Checklist (100 Points)
Panacea Biotec Ltd • Updated: 2025-09-17 16:05:50
-
10BusinessHighPharmaceutical sector is growing, but competition is intense.
-
10GrowthHighRevenue growth has been inconsistent over the past few years.
-
10ProfitabilityHighROE and ROCE are below industry averages.
-
8ValuationHighP/E ratio is higher than peers, indicating overvaluation.
-
7BalanceHighModerate debt levels, but liquidity is a concern.
-
6GovernanceGoodPromoter holding is decent, but some pledging exists.
-
5DriversGoodLimited growth catalysts identified.
-
5TechnicalsGoodWeak momentum and low liquidity in trading.
Final Score & Verdict
Score 68 / 100
• Decent
Panacea Biotec Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 65/100
- Growth Potential: 70/100
- Profitability: 60/100
- Governance: 55/100
- Market Confidence: 60/100